Additional information
Grey Powder
59654-17-0
ACI-025603
218.2-221.4°C
C9H18N2O2S.2HBr
380.14
Ambient
2-8°C
Prostaglandin
Pharmaceutical Impurity Standards
5-[(2S,3S,4R)-3,4-diaminothiolan-2-yl]pentanoic acid dihydrobromide
5-[(2S,3S,4R)-3,4-Diaminothiolan-2-yl]pentanoic acid
2-Thiophenepentanoic acid, 3,4-diaminotetrahydro-, dihydrobromide, (2S,3S,4R)






![Ethyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethylsulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate](https://staging.analyticachemie.in/wp-content/uploads/1A06130-150x150.png)


![2-sec-butyl-4-{4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl}-2H-1,2,4-triazol-3(4H)-one](https://staging.analyticachemie.in/wp-content/uploads/1A06380-150x110.png)
![Abiraterone Isopropyl Ether (25 mg) (3-((3S,8R,9S,10R,13S,14S)-3-isopropoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine; 3beta-Isopropoxy-17-(pyridin-3-yl)androsta-5,16-diene)](https://staging.analyticachemie.in/wp-content/uploads/image-1-150x145.png)